Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Total Liabilities (2019 - 2026)

Pliant Therapeutics has reported Total Liabilities over the past 8 years, most recently at $37.4 million for Q1 2026.

  • Quarterly Total Liabilities fell 57.27% to $37.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $37.4 million through Mar 2026, down 57.27% year-over-year, with the annual reading at $44.0 million for FY2025, 52.6% down from the prior year.
  • Total Liabilities was $37.4 million for Q1 2026 at Pliant Therapeutics, down from $44.0 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $99.8 million in Q3 2024 and troughed at $23.2 million in Q1 2022.
  • The 5-year median for Total Liabilities is $41.8 million (2023), against an average of $57.9 million.
  • Year-over-year, Total Liabilities skyrocketed 213.83% in 2022 and then crashed 57.27% in 2026.
  • A 5-year view of Total Liabilities shows it stood at $37.3 million in 2022, then grew by 3.51% to $38.6 million in 2023, then surged by 140.73% to $92.9 million in 2024, then plummeted by 52.6% to $44.0 million in 2025, then decreased by 14.98% to $37.4 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Total Liabilities are $37.4 million (Q1 2026), $44.0 million (Q4 2025), and $76.3 million (Q3 2025).